A chimeric anti-CEA antibody with heavy interchain disulfide bonds deleted: Molecular characterization and biodistributions in normal and tumor bearing mice

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 13-21

  Neumaier, Michael ^a   Gaida, Franz Joseph ^a   Lewis, Michael R ^b   Hefta, Laura J ^b   Shively, Louise E ^b   Raubitschek, Andrew ^b   Shively, John E ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Biodistributions; Biosensor; Carcinoembryonic antigen (CEA); Mass spectrometry; Recombinant antibody

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIBODY; CYSTEINE; GLYCINE; INDIUM 111; ISOTHIOCYANIC ACID DERIVATIVE; PENTETIC ACID DERIVATIVE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOREACTOR; BIOSENSOR; CHEMICAL STRUCTURE; CONTROLLED STUDY; DISULFIDE BOND; GEL ELECTROPHORESIS; GEL FILTRATION; MOLECULAR SIZE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; BIOSENSING TECHNIQUES; CARCINOEMBRYONIC ANTIGEN; DISULFIDES; HUMANS; MICE; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 0032946563     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Bischof-Delaloye D, Delaloye B, Buchegger F, Gilgien W, Studer A, Curchod S, Givel JC, Mosimann F, Pettavel J and Mach J-P: Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 30: 1646-1656, 1989.
2. Murray JL, Rosenblum MG, Zhang H.-Z, Podoloff DA, Kasi LP, Curley SA, Chan JC, Roh M, Hohn DC, Brewer H, Cunningham JE, Thompson LB, Bhadkamkar V, Pinsky CM and Fogler WE: Comparative tumor localization of whole immunoglobulin G anti-carcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients, Cancer (Suppl.) 73: 850-857, 1994.
3. Patt YZ, lamki LM and Haynie TP: Improved localization of Indium-111 labeled monoclonal anti-carcinoembryonic antigen ZCE-025 in metastatic colorectal cancer, J Clin Oncol 6: 1220-1230, 1988.
4. Beatty JD, Duda RB, Williams LEKS, Paxton RJ, Beatty BG, Philben VJ, Wemer JL, Shivery JE, Vlahos WG, Kokal WA, Riihimaki DU, Terz JJ and Wagman LD: Preoperative imaging of colorectal carcinoma with In-111 labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 46: 6469-6502, 1986.
5. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C and Murray JL: Imaging with indium-111 labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases, J Clin Oncol 8: 1246-1254, 1990.
6. Divgi CR, McDemmott K, Griffin TW, Johnson DK, Schnobrich KE, Fallone PS, Scott AM, Hilton S, Cohen AM and Larson SM: Lesion by lesion comparison of computerized tomography and indium-111 labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial. J Nucl Med 34: 1656-1661, 1993.
7. Lane DM, Eagle KF, Begent RHJ, Hope-Stone LD, Green AJ, Casey JL, Keep PA, Kelly AMB, Ledermann JA, Glaser MG and Hilson AJW: Radioimmunotherapy of metastatic colorectal tumors with iodine-131 labeled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer 70: 521-525, 1994.
8. Juweid M, Sharkey RM, Alavi A, Swaync LC, Herskovic T, Hanley D, Rubin AD, Pereira M and Goldenberg DM: Regression of advanced refractory ovarian cancer treated with iodine-131 labeled anti-CEA monoclonal antibody. J Nucl Med 38: 257-260, 1997.
9. 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res (Suppl.) 55: 5946s-5951s, 1995.
10. Hyams DM, Esteban JM, Lollo CP, Beatty BG and Beatty JD: Therapy of peritoneal carcinomatosis of human colon acncer xenografts with Yttrium-90 labeled anti-carcinoemhryonic antigen antibody ZCE025. Arch Surg 122: 1333-1337, 1987.
11. Morton BA, Beatty BG, Mison AP, Wanek PM and Beatty JD: Role of bone marrow transplant in yttrium-90 antibody therapy of colon cancer xenografts in nude mice. Cancer Res (Suppl.) 50: 1008s-1010s, 1990.
12. Wong JYC, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, Wu AM, Johnson DK, Primus FJ, Shively JE and Raubitschek AA: Initial experience evaluating 90-Yttrium radiolabelled anti-carcinoembryonic antigen chimeric T84.66 in a Phase I radioimmunotherapy trial. Cancer Res (Suppl.) 55: 5929s-5934s, 1995.
13. Buchegger F, Pelegrin A, Delaloye B, Bischof-Delaloye A and Mach J-P: Iodine-131 labeled Mab F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 31: 1035-1044, 1990.
14. Buchegger F, Haskell CM, Scgreyer M, Scaziga BR, Randin S, Carrel S and Mach JP: Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 158: 413-427, 1983.
15. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody fragments in nude mice. Cancer Res 47: 1691-1694, 1987.
16. Lamki LM, Patt YZ, Rosenblum MG, Shanken LJ, Thompson LB, Scheighardt SA, Frincke JM and Murray JL: Metastalic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment on an anti-CEA monoclonal antibody. Radiology 174: 147-151, 1990.
17. Moffat FL, Vargas-Cuba RD, Serafini AN, Casillas VJ, Morillo G, Benedetto P, Robinson DS, Ardalan B, Manten HD, Clark KC, Garrido J, Ketcham AS and Pinsky CM: Radioimmunodetection of colorectal carcinoma using technetium-99m labeled Fab' fragments of the immu-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer (Suppl.) 73: 836-845, 1994.
18. Milenic DE, Yokota T, Filupa DR, Finkelman MAJ, Dodd SW, Wood JF, Whitlow M, Snoy P and Schlorn J: Construction, binding properties, metabolism, and tumor targeting of a single chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51: 6363-6371, 1991.
19. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF III, Bookman MA, Fand I, Houston LL and Weiner LM: Highly specific in vivo tumor targetting by monovalent and divalent forms of 741 F8 anti-c-erbB-2 single chain Fv. Cancer Res 53: 4026-4034, 1993.
20. Wu AM, Chen W, Raubitschek AA, Williams LE, Fischer R, Neumaier M, Hu S-Z, Odom-Maryon T, Wong JYC and Shively JE: Tumor localization of anti-CEA single chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2: 21-36, 1996.
21. Hu S-Z, Shively LE, Raubitschek AA, Sherman M, Williams LE, Wong JYC, Shively JE and Wu AM: A novel engineered anti-CEA antibody fragment (single chain Fv-CH3) which exhibits rapid, high level targeting of xenografts. Cancer Res 56: 3055-3061, 1996.
22. Morton BA, O'Connor-Tressel M, Beatty BG, Shively JE and Beatty JD: Artifactual CEA elevation due to human anti-mouse antibodies. Arch Surg 123: 1242-1246, 1988.
23. Lo Buglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J and Khazaeli MB: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86: 4220-4224, 1989.
24. Sears H, Herlyn D, Steplewski Z and Koprowski H: Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Modifiers 3: 138-150, 1984.
25. Losman MJ, DeJager RJ, Monestier M, Sharkey RM and Goldenberg DM: Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies. Cancer Res (Suppl.) 50: 1055s-1058s, 1990.
26. Morrison SL: Transfectomas provide novel chimeric antibodies. Science 229: 1201-1210, 1985.
27. Jones PT, Dear PH, Foote J, Neuberger MS and Winter G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525, 1986.
28. Verhoeyen M, Milstein C and Winter G: Reshaping human antibodies: grafting an anti-lysozyme activity. Science 239: 1534-1536, 1988.
29. Neumaier M, Shively L, Chen F-S, Gaida F-J, Ilgen C, Paxton RJ, Shively JE and Riggs AD: Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and chinese hamster ovary cells. Cancer Res 50: 2128-2134, 1990.
30. 111In or 90Y labeled chimneric anti-CEA monoclonal antibody (cT84.66) following its large scale production in a bioreactor. TumorTargeting 2: 116-124, 1996.
31. Hardman N, Gill LL, DeWinter RFJ, Wagner K, Hollis M, Businger F, Ammaturo D, Buchegger F, Mach J-P and Heusser C: Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen. Int J Cancer 44: 424-433, 1989.
32. Beidler CN, Ludwig JR, Cardenas J, Phelps J, Papworth CG, Melcher E, Sierzega M, Myers LJ, Unger BW, Fisher M, David GS and Johnson MJ: Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen. J Immunology 141: 4053-4060, 1988.
33. Koga H, Kanda H, Nakashima M, Watanabe Y, Endo K and Watanabe T: Mouse-human chimeric monoclonal antibody to carcinoembryonic antigen (CEA): in vitro and in vivo activities. Hybridoma 9: 43-56, 1990.
34. Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, Wong GY, Blumenthal RD, Griffiths GL, Siegel JA, Leung S, Hansen HJ and Goldenberg DM: Evaluation of a complementary-determining region grafted (humanized) anti-carcinomebryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res (Suppl.) 55: 5935s-5945s, 1995.
35. Ayala M, Duenas M, Santos A, Vazquez J, Menedcz A, Silva A and Gavilondo JV: Bacterial single-chain antibody fragments, specific for carcinoembryonic antigen. Biotechniques 13: 790-799, 1992.
36. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R and Oppermann H: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produce in Escherichia coli. Proc Natl Acad Sci USA 85: 5874-5883, 1988.
37. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS and Whitlow M: Single-chain antigen-binding proteins. Science 242: 423-426, 1988.
38. Horwitz AH, Chang CP, Better M, Hellstrom KF, and Robinson R: Secretion of functional antibody and Fab fragment from yeast cells. Proc Natl Acad Sci USA 85: 8687-8682, 1988.
39. Better M, Chang CP, Robinson R and Horowitz AH: Escherichia coli secretion of an active chimeric antibody fragment. Science 240: 1041-1043, 1988.
40. Barbas CF III, Crowe JE Jr, Cabab D, Jones TM, Zehedee SL, Murphy BR, Chanock RM and Burton DR: Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory synctial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci USA 89: 10164-10168, 1992.
41. Mueller BM, Reisfeld RA and Gillies SD: Serum half life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci 87: 5702-5705, 1990
42. Kunkel TA: Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci 82: 488-492, 1985.
43. Sanger F, Nicklen S and Coulson R: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467, 1977.
44. Gaida F-J, Fenger U, Wagener C and Neumaier M: A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen. Int J Cancer 51: 459-465, 1992.
45. Laemmli U: Cleavage of the structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
46. Haas GM, Bolling TJ, Kinders RJ, Henslee JG, Mandecki W, Dorwin SA and Shively JE: Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use in epitope mapping. Cancer Res 51: 1876-1882, 1991.
47. Westerberg DA, Carney PL, Rogers PE, Kline SJ and Johnson DK: Synthesis of novel bifunctional chelators and their use in preparing monoclonal antibody conjugates for tumor targeting. J Med Chem 32: 236-243, 1988.
48. Meares CF, McCall MJ, Reardon DT, Qoodwin DA, Diamanti CI, and McTigue M: Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis and subsequent addition of metal ions. Anal Biochem 142: 68-78, 1984.
49. Dorai H, Wesolowski JS and Gillies SD: Role of inter-heavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1. Mol Immunol 29: 1487-1491, 1992.
50. Kim J-K, Tsen M-F, Ghetie V and Ward S: Evidence that the hinge region plays a role in maintaining serum levels of the murine IgG1 molecule. Mol Immunol 32:467-475, 1995.
51. Rowe ES: Dissociation and denaturation equilibria and kinetics of a homogeneous human immunoglobulin Fab fragment. Biochemistry 15: 905-916, 1976.
52. Bigelow CC, Smith BR and Dorrington KJ: Equilibrium and kinetic aspects of subunit association in immunoglobulin G. Biochemistry 13: 4602-4608.
53. Petersen JG and Dorrington KJ: An in vitro system for studying the kinetics of interchain disulfide bond formation in immunoglobulin G. J Biol Chem 249: 5633-5641, 1974.
54. Mujoo K, Cheresh DA, Yang HA and Reisfeld RA: Disialoganglioside GD2 on neuroblastoma cells: target antigen for monoclonal antibody mediated cytloysis and suppression of tumor growth. Cancer Res 47: 1098-1104, 1987.